Kathryn Collinet

Kathryn Collinet

Kathryn Collinet, PhD, is a Technical and Marketing Writer for Personalized Healthcare and Oncology at QIAGEN. She trained as a molecular biologist at the University of Barcelona and the Institute for Research in Biomedicine, where she studied DNA and protein modifications and their influence on chromatin conformation and gene expression. Since 2011 Kathryn has been working in marketing communications for the scientific information and molecular diagnostics industries. Kathryn has a passion for delivering knowledge and insights about molecular and clinical technologies, and their power to impact research and healthcare.

Webinar: A clinical view on PITX2 DNA methylation in high-risk breast cancer

A webinar program for oncologists and pathologists Thursday, Feb. 22, 2018 at 1:00 p.m. CET Anthracycline-based chemotherapy is the recommended standard-of-care for certain high-risk breast cancer patients including lymph node-positive, estrogen receptor-positive and HER2-negative high-risk breast cancer patients. However, not all patients benefit equally from this chemotherapy. Learn more about a novel, validated marker that… Read article →


PITX2: A novel biomarker to support breast cancer therapy selection

PITX2 DNA methylation status is a clinically relevant biomarker to predict survival in a variety of cancers, including breast cancer, and is a predictive biomarker for treatment response in high- risk breast cancer patients. Applying PITX2 methylation as a predictive biomarker can help avoid use of chemotherapy in patients that would receive  little or no… Read article →


Multi-center study shows QIAGEN’s ipsogen JAK2 MutaQuant Kit is robust, efficient and sensitive for quantitative detection of the JAK2 V617F mutation

A network study of multiple laboratories finds the ipsogen JAK2 MutaQuant Kit to be robust, efficient and sensitive for quantitative detection of the JAK2 V617F mutation. This study sets the basis for the standardization of molecular techniques for JAK2 V617F determination. The JAK2 V617F mutation is an important diagnostic biomarker for Philadelphia (Ph)- negative myeloproliferative… Read article →













QIAGEN’s GeneReader NGS System gains further validation in oncology research applications with new independent performance review data

Studies presented at AMP Global conference in Berlin reaffirm powerful analytical performance and ease of use for the world’s first complete Sample to Insight NGS solution Hilden, Germany, April 3, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced further validation of the GeneReader NGS System with the publication of five new… Read article →


QIAGEN launches first FDA-cleared JAK2 test for certain type of leukemia

New biomarker test – the fifth QIAGEN oncology test with FDA clearance in the U.S. – designed to aid diagnosis of patients suspected of having Polycythemia Vera form of blood cancer Germantown, Maryland, and Hilden, Germany, March 29, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. launch of its ipsogen® JAK2 RGQ… Read article →


QIAGEN at AMP Global 2017

The inaugural AMP Global Congress on Molecular Pathology, hosted by the Association for Medical Pathologists (AMP), is the event of the year for molecular pathology, diagnostic technologies and research and clinical applications. AMP Global 2017 is the perfect event for QIAGEN to remind and educate the market about our broad menu of Sample to Insight… Read article →



Large global patient study confirms circulating tumor DNA feasible for EGFR mutation analysis

EGFR mutation testing of tumor sample DNA from patients with nonsquamous advanced NSCLC is advocated by clinical guidelines (1, 2) and working groups (3, 4) and is required to confirm whether patients should receive EGFR tyrosine kinase inhibitor (TKI) treatment. However, tissue samples are not always available or evaluable for diagnosis and mutation testing, leaving… Read article →


Pyrosequencing for MGMT promoter methylation analysis validated for use in clinical practice

Pyrosequencing is reported as the ideal method for MGMT methylation analysis, and is validated for use in clinical practice. Methylation of the O6-methylguanine- DNA-methyltranferase (MGMT) promoter region is associated with several cancer types, including colorectal cancer, lung cancer, lymphoma and glioblastoma. MGMT promoter methylation is a powerful predictive biomarker of positive response to temozolomide, a… Read article →


Leading Innovation in Biomarker Testing: Next-Generation Sequencing (NGS)

Cutting edge approaches such as NGS are the future of biomarker testing, but require expertise from industry leaders like QIAGEN to develop. QIAGEN’s biomarker assays are designed to ease the challenges faced by those who perform the tests. By engaging with stakeholders, such as laboratorians and oncologists, QIAGEN’s diagnostic assays aim to deliver multiple benefits… Read article →


QIAGEN launches unique CALR mutation assay for MPN diagnosis

European launch of the new CE marked ipsogen CALR RGQ PCR Kit to improve MPN diagnosis for leukemia patients in line with latest WHO recommendations and clinical guidelines HILDEN, Germany, Dec. 1, 2016 – QIAGEN today announced the European launch of a unique CE-IVD marked calreticulin (CALR) mutation assay to aid in establishing the diagnosis… Read article →


Leading Innovation in Biomarker Testing: Liquid Biopsy

Cutting edge approaches which use techniques such as liquid biopsy are the future of biomarker testing, but require expertise and leadership to develop. QIAGEN’s companion diagnostic assays are designed to ease the challenges faced by pathologists in labs performing the tests. By engaging with stakeholders, such as laboratorians and oncologists, QIAGEN’s diagnostic assays aim to… Read article →


QIAGEN’s NGS solutions highlighted at the annual Congress of the European Society of Pathology

QIAGEN’s broad portfolio of Sample to Insight solutions for NGS were a focus at the QIAGEN booth and industry symposium at this year’s annual Congress of the European Society of Pathology. The XXXI International Congress of the International Academy of Pathology (IAP) and 28th Congress of the European Society of Pathology (ESP) was hosted for… Read article →


The Prognostic Significance of Gene Mutations in Myeloproliferative Neoplasms

Relevant gene mutations in MPN and their prognostic significance for primary myelofibrosis (PMF). Myeloproliferative neoplasms (MPN) are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. MPN include (primary) myelofibrosis (PMF), essential thrombocythemia (ET) and polycythemia vera (PV), and affect around 13,000, 134,000 and 148,000 patients… Read article →


Large global patient study confirms circulating tumor DNA feasible for EGFR mutation analysis

EGFR mutation testing of tumor sample DNA from patients with nonsquamous advanced NSCLC is advocated by clinical guidelines (1, 2) and working groups (3, 4) and is required to confirm whether patients should receive EGFR tyrosine kinase inhibitor (TKI) treatment. However, tissue samples are not always available or evaluable for diagnosis and mutation testing, leaving… Read article →


WT1 expression and NPM1 mutations as biomarkers for minimal residual disease (MRD) monitoring in AML patients

The AML Global Portal highlights the value of AML biomarkers WT1 expression and NPM1 mutation for MRD monitoring in AML patients The AML_Global_Portal is an evidence-based online resource committed to informing and educating health care providers about the latest cutting-edge advancements in acute myeloid leukemia (AML). The portal aims to help advance understanding and share… Read article →


QIAGEN at ESMO 2016

Meet us there to discuss how our next-generation oncology solutions can take you from sample to insight! The ESMO_2016_Meeting is just around the corner, and we’re excited to see you there from Oct. 7 – 11 in Copenhagen! Here at QIAGEN, we are proud to be part of the collaborative effort to improve cancer care…. Read article →


Improved research and diagnostics could help reduce the economic burden of blood disorders

Since the arrival of personalized healthcare and molecular diagnostics, there has been growing support for utilizing DNA, RNA, and protein-based biomarker detection methods as a means to help reduce rising healthcare costs (1). Molecular diagnostics can help select the right patients for the right treatments, and define which patients require costly confirmatory diagnostic tests. In… Read article →


QIAGEN is at ECP 2016 in Cologne!

Meet us there to discuss the new NGS solution to cancer research – our Sample to Insight approach! This year the XXXI International Congress of the International Academy of Pathology (IAP) and the 28th Congress of the European Society of Pathology (ESP) is being hosted as a joint venture in Cologne from September 25–29 (see conference… Read article →